China Completes First 'Medicare-Priced' Brain-Computer Interface Surgery; BeiGene Submits NDA for Novel BCL2 Inhibitor in the U.S.
BeOne
Developer of Molecular Targeted and Immune Anti-Tumor Drugs
BAO PHARMA
Biopharmaceutical R&D and Manufacturer
IASO Biotechnology
Cancer Treatment New Drug Developer
© Amino Observation - Innovative Drug Team Original Production
Author | Huang Kai
New Progress in Brain-Computer Interface.
On November 26, the first brain-computer interface surgery in China, performed under government-approved medical service pricing, was successfully completed at the Department of Neurosurgery, Tongji Hospital, Huazhong University of Science and Technology. The surgery utilized an implantable brain-computer interface device produced by Wuhan Zhonghua Brain-Computer Fusion Technology Development Co., Ltd., which can be used to monitor brain signals from the motor and sensory areas of the hand region in the brain.
BeOne Medicines Submits Another Major Drug for Market Approval in the United States.
On November 26, BeOne Medicines announced that the FDA has accepted the New Drug Application (NDA) for the next-generation BCL2 inhibitor, Sotoclax, and granted it priority review status. It is intended for the treatment of patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) who have received Bruton's tyrosine kinase (BTK) inhibitor therapy.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) China's First "Medical Insurance Price" Brain-Computer Interface Surgery Completed
On November 26, the first brain-computer interface surgery in China, carried out according to government-approved medical service pricing, was successfully completed at the Department of Neurosurgery, Tongji Hospital, Huazhong University of Science and Technology. The surgery utilized an implantable brain-computer interface device produced by Wuhan Zhonghua Brain-Computer Fusion Technology Development Co., Ltd., which can be used to monitor brain signals in the motor and sensory regions associated with hand movement.
/ 02 /
Capital Information
1) BAO PHARMA Passes HKEX Hearing
On November 26, according to the HKEX official website, BAO PHARMA passed the HKEX listing hearing.
/ 03 /
Pharmaceutical News
1) Lilly's Olomorasib Capsule Receives Clinical Approval
On November 27, according to the CDE official website, Eli Lilly's Olomorasib capsule received clinical approval for use in combination with Amivantamab injection (subcutaneous injection) for the treatment of patients with metastatic non-small cell lung cancer harboring KRAS G12C mutations.
2) YKYY018 Nebulizer Inhalant from Yookang Pharmaceuticals Receives FDA Approval for Clinical Trials
On November 27, Yooking Pharmaceuticals announced that the FDA has approved the clinical use of YKYY018 nebulized inhalation solution for the prevention and treatment of respiratory syncytial virus (RSV) infection.
3) IASO Bio's Fokosu Approved for Marketing by the Hong Kong Department of Health
On November 27, IASO Bio announced that its self-developed fully human BCMA-targeted CAR-T cell therapy product Fucaso (Idecabtagene Vicleucel Injection) has been approved for marketing by the Hong Kong Department of Health. It is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have progressed after receiving at least three prior lines of therapy.
4) BeOne Medicines' BCL2 Inhibitor Submitted for Market Approval in the United States
On November 26, BeOne Medicines announced that the FDA has accepted the New Drug Application (NDA) for the next-generation BCL2 inhibitor, Sotoclax, and granted it priority review status. It is intended for the treatment of patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) who have been treated with Bruton's tyrosine kinase (BTK) inhibitors.
PS: Welcome to scan the QR code below to add the WeChat ID of AminoGenius for communication.
